Krystal Biotech, Inc. (NASDAQ:KRYS) Receives Consensus Rating of "Buy" from Brokerages

Krystal Biotech, Inc. (NASDAQ:KRYS - Get Free Report) has received an average recommendation of "Buy" from the eight ratings firms that are presently covering the company, MarketBeat reports. One investment analyst has rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. The average 1-year target price among brokers that have issued ratings on the stock in the last year is $206.67.

Several analysts have recently commented on the stock. HC Wainwright restated a "buy" rating and issued a $221.00 target price on shares of Krystal Biotech in a research note on Wednesday, December 18th. Citigroup raised their price objective on shares of Krystal Biotech from $204.00 to $206.00 and gave the company a "neutral" rating in a research report on Tuesday, November 5th. Stifel Nicolaus boosted their target price on Krystal Biotech from $204.00 to $220.00 and gave the stock a "buy" rating in a research report on Wednesday, September 11th. Finally, Chardan Capital reissued a "buy" rating and issued a $212.00 price target on shares of Krystal Biotech in a report on Wednesday, December 18th.

Krystal Biotech Stock Down 2.0 %

NASDAQ:KRYS traded down $3.14 during trading hours on Wednesday, reaching $156.66. 206,227 shares of the company's stock were exchanged, compared to its average volume of 322,049. Krystal Biotech has a 1-year low of $107.50 and a 1-year high of $219.34. The firm has a market capitalization of $4.51 billion, a price-to-earnings ratio of 88.51 and a beta of 0.80. The company has a 50-day moving average of $177.22 and a 200 day moving average of $184.30.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last announced its earnings results on Monday, November 4th. The company reported $0.91 earnings per share for the quarter, topping the consensus estimate of $0.84 by $0.07. The business had revenue of $83.84 million during the quarter, compared to the consensus estimate of $82.94 million. Krystal Biotech had a net margin of 21.68% and a return on equity of 7.54%. The business's quarterly revenue was up 879.9% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.67) earnings per share. Research analysts forecast that Krystal Biotech will post 2.97 EPS for the current fiscal year.

Insider Buying and Selling

In other news, insider Suma Krishnan sold 25,000 shares of Krystal Biotech stock in a transaction on Friday, December 13th. The stock was sold at an average price of $164.78, for a total transaction of $4,119,500.00. Following the completion of the transaction, the insider now owns 1,475,882 shares of the company's stock, valued at $243,195,835.96. The trade was a 1.67 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Insiders own 14.10% of the company's stock.

Hedge Funds Weigh In On Krystal Biotech

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Arizona State Retirement System raised its holdings in shares of Krystal Biotech by 2.1% in the second quarter. Arizona State Retirement System now owns 5,147 shares of the company's stock worth $945,000 after acquiring an additional 108 shares during the last quarter. Fiera Capital Corp raised its stake in Krystal Biotech by 0.8% in the 2nd quarter. Fiera Capital Corp now owns 16,208 shares of the company's stock valued at $2,976,000 after purchasing an additional 130 shares during the last quarter. KBC Group NV lifted its holdings in Krystal Biotech by 25.9% in the 3rd quarter. KBC Group NV now owns 642 shares of the company's stock valued at $117,000 after purchasing an additional 132 shares in the last quarter. Profund Advisors LLC boosted its stake in shares of Krystal Biotech by 1.6% during the 2nd quarter. Profund Advisors LLC now owns 8,693 shares of the company's stock worth $1,596,000 after purchasing an additional 140 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in shares of Krystal Biotech by 3.4% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 4,614 shares of the company's stock worth $840,000 after buying an additional 153 shares in the last quarter. Institutional investors and hedge funds own 86.29% of the company's stock.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).